- Home
- AKBA vs WGO Comparison
AKBA vs WGO Comparison
Compare AKBA & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- WGO
- Stock Information
- Founded
- AKBA 2007
- WGO 1958
- Country
- AKBA United States
- WGO United States
- Employees
- AKBA N/A
- WGO N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- WGO Homebuilding
- Sector
- AKBA Health Care
- WGO Industrials
- Exchange
- AKBA Nasdaq
- WGO Nasdaq
- Market Cap
- AKBA 861.7M
- WGO 893.6M
- IPO Year
- AKBA 2014
- WGO N/A
- Fundamental
- Price
- AKBA $2.88
- WGO $31.51
- Analyst Decision
- AKBA Strong Buy
- WGO Buy
- Analyst Count
- AKBA 5
- WGO 12
- Target Price
- AKBA $6.90
- WGO $39.36
- AVG Volume (30 Days)
- AKBA 2.9M
- WGO 489.7K
- Earning Date
- AKBA 11-06-2025
- WGO 10-22-2025
- Dividend Yield
- AKBA N/A
- WGO 4.23%
- EPS Growth
- AKBA N/A
- WGO N/A
- EPS
- AKBA N/A
- WGO N/A
- Revenue
- AKBA $203,733,000.00
- WGO $2,741,800,000.00
- Revenue This Year
- AKBA $43.91
- WGO N/A
- Revenue Next Year
- AKBA $32.09
- WGO $5.80
- P/E Ratio
- AKBA N/A
- WGO N/A
- Revenue Growth
- AKBA 16.75
- WGO N/A
- 52 Week Low
- AKBA $1.26
- WGO $28.00
- 52 Week High
- AKBA $4.08
- WGO $65.65
- Technical
- Relative Strength Index (RSI)
- AKBA 47.89
- WGO 39.06
- Support Level
- AKBA $2.83
- WGO $32.91
- Resistance Level
- AKBA $3.02
- WGO $35.10
- Average True Range (ATR)
- AKBA 0.12
- WGO 1.08
- MACD
- AKBA 0.03
- WGO -0.26
- Stochastic Oscillator
- AKBA 56.94
- WGO 10.03
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About WGO Winnebago Industries Inc.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was nearly $3 billion in fiscal 2024. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 83% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total RV unit volume was 38,796 in fiscal 2024. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.